Inhibition of HIV-1 replication by primer RNA packaging inhibitors

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Human immunodeficiency virus type 1 (HIV-1) replication relies on packaging transfer RNA (tRNA)₃^Lys during viral assembly.
• This packaging process involves a complex of GagPol, mitochondrial lysyl-tRNA synthetase, and tRNA₃^Lys, crucial for initiating reverse transcription.
• Current HIV therapies target various viral life cycle stages, but novel strategies are needed to overcome resistance.

Purpose of the Study:

• To identify molecules that inhibit the interaction between GagPol and mitochondrial lysyl-tRNA synthetase.
• To evaluate the efficacy of these molecules in blocking HIV-1 replication.
• To explore the potential of targeting the tRNA packaging step for new antiviral drug development.

Main Methods:

• An in vitro assay was employed to screen a chemical library for inhibitors of the GagPol-lysyl-tRNA synthetase interaction.
• Selected inhibitor molecules were tested for their ability to inhibit HIV-1 replication in ex vivo assays.
• Viral particle production, infectivity, and tRNA₃^Lys content were analyzed in the presence of the identified inhibitors.

Main Results:

• Three molecules were isolated that effectively disrupt the target interaction.
• These molecules significantly reduced HIV-1 particle production (IC₅₀ at 5 µM) and infectivity.
• Inhibitor treatment led to decreased tRNA₃^Lys packaging into virions, resulting in replication-defective particles.

Conclusions:

• The HIV-1 tRNA packaging step is a viable target for antiviral drug development.
• The identified molecules represent a new class of HIV-1 inhibitors with a novel mechanism of action.
• These inhibitors offer potential for developing drugs with unique resistance profiles against HIV-1.